Clearpoint Neuro Inc (CLPT)vsDexCom Inc (DXCM)
CLPT
Clearpoint Neuro Inc
$14.58
+3.11%
HEALTHCARE · Cap: $450.74M
DXCM
DexCom Inc
$74.54
-0.80%
HEALTHCARE · Cap: $29.58B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 11763% more annual revenue ($4.82B vs $40.61M). DXCM leads profitability with a 19.3% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. DXCM earns a higher WallStSmart Score of 72/100 (B).
CLPT
Hold37
out of 100
Grade: F
DXCM
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.2%
Fair Value
$14.88
Current Price
$14.58
$0.30 discount
Margin of Safety
+89.6%
Fair Value
$656.95
Current Price
$74.54
$582.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.9% year-over-year
Growing faster than its price suggests
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 23.1x book value
ROE of -154.3% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 9.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : CLPT
The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
CLPT profiles as a hypergrowth stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
CLPT is growing revenue faster at 42.9% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 37/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?